ArticleBMC medical genomics2025
Clinical use of whole-genome sequencing in children with developmental delay or intellectual disability.
Article in BMC medical genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDetermining the underlying cause of developmental delay or intellectual disability (DD/ID) is challenging yet crucial. Establishing a genetic basis for cases of unexplained DD/ID is integral to informing clinical decisions and anticipating patient outcomes. In this report, we share our institutional insights derived from employing whole-genome sequencing (WGS) to investigate unexplained DD/ID in pediatric populations.
methodsA retrospective study was conducted on 115 children aged 1 month to 16 years with unexplained DD/ID who underwent WGS. We analyzed demographic profiles and catalogued genetic variants identified, in conjunction with examining clinical variables potentially associated with diagnostic yield.
resultsWGS data from 115 pediatric patients identified a total of 33 pathogenic or likely pathogenic single nucleotide variants and small insertions/deletions, of which 22 were classified as diagnostic cases and 11 as carriers. In addition, 11 pathogenic or likely pathogenic copy number variations were detected. Clinical attributes such as gender, age at diagnosis, gestational maturity, birth weight, perinatal complications (anoxia, jaundice), comorbid symptoms, hereditary background, neuromuscular function (muscle tone and strength), presence of epilepsy, neuroimaging, and electroencephalography patterns did not show a significant association with WGS findings. Nonetheless, a noteworthy association emerged between earlier age at diagnosis and increased diagnostic yield via WGS.
conclusionsWGS serves as a powerful tool for uncovering genetic etiologies in children with unexplained DD/ID, with meaningful implications for clinical care, genetic counseling for families, and long-term management planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.